Current therapy of pulmonary and disseminated fungal diseases.
D000666:Amphotericin B / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D001759:Blastomycosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D002862:Chromoblastomycosis / Q000188:drug therapy; D003047:Coccidioidomycosis / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy; D005437:Flucytosine / Q000378:metabolism / Q000627:therapeutic use; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D007654:Ketoconazole; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008825:Miconazole / Q000378:metabolism / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000935:Antifungal Agents; D007093:Imidazoles; D010879:Piperazines; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine; D007654:Ketoconazole